- ISIN
- US1712691039
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
Highlights
- Market Cap
- $75.57B
- Enterprise Value
- $73.09B
- EPS (TTM)
- ¥144.42
- PE Ratio
- 25.69
- PEG Ratio
- 2.19
- Total Revenue (TTM)
- ¥1.36T
- Gross Profit (TTM)
- ¥970.13B
- EBITDA (TTM)
- ¥699.55B
- Year Range
- $19.50 - $34.84
- ROA (TTM)
- 20.90%
- ROE (TTM)
- 24.81%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CHGCY Performance Chart
Chugai Pharmaceutical Co Ltd ADR (CHGCY) is down 12.6% since the beginning of the year. At $23 per share, CHGCY is trading 34.1% below its 52-week high of $35. Investors who bought $1,000 worth of CHGCY shares 5 years ago would now be looking at an investment worth $1,211.
Loading charts...
Returns By Period
Chugai Pharmaceutical Co Ltd ADR (CHGCY) has returned -12.60% so far this year and -9.37% over the past 12 months. Looking at the last ten years, CHGCY has achieved an annualized return of 16.03%, outperforming the S&P 500 Index benchmark, which averaged 13.71% per year.
Chugai Pharmaceutical Co Ltd ADR
- 1D
- -1.29%
- 1M
- -9.50%
- YTD
- -12.60%
- 6M
- -14.04%
- 1Y
- -9.37%
- 3Y*
- 17.26%
- 5Y*
- 3.91%
- 10Y*
- 16.03%
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
CHGCY Monthly Returns History
Based on dividend-adjusted daily data since Nov 23, 2010, CHGCY's average daily return is +0.07%, while the average monthly return is +1.48%. At this rate, an investment would double in approximately 3.9 years.
Historically, 50% of months were positive and 50% were negative. The best month was Jul 2014 with a return of +28.1%, while the worst month was Dec 2014 at -20.5%. The longest winning streak lasted 12 consecutive months, and the longest losing streak was 4 months.
On a daily basis, CHGCY closed higher 28% of trading days. The best single day was Oct 2, 2018 with a return of +25.9%, while the worst single day was Aug 7, 2025 at -20.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 8.68% | 17.72% | -18.12% | -0.22% | -10.12% | -6.97% | -12.60% | ||||||
| 2025 | -1.64% | 15.78% | -9.11% | 26.43% | -9.29% | 1.60% | -7.63% | -9.09% | 1.01% | 3.39% | 16.89% | -1.68% | 21.53% |
| 2024 | -4.88% | 11.10% | -3.97% | -17.20% | -3.91% | 16.75% | 22.68% | 15.32% | -4.18% | -1.08% | -7.68% | 0.72% | 17.55% |
| 2023 | 1.89% | -3.95% | -0.97% | 4.56% | 4.60% | 6.03% | 4.85% | 2.14% | 0.92% | -3.57% | 18.26% | 7.41% | 48.78% |
| 2022 | -0.79% | 2.53% | 0.12% | -10.38% | -9.31% | -5.69% | 9.59% | -7.82% | -3.57% | -7.23% | 14.21% | -2.72% | -21.63% |
| 2021 | -0.19% | -15.52% | -9.52% | -7.85% | 1.38% | 5.02% | -7.68% | 6.09% | -5.85% | 1.63% | -13.16% | 0.96% | -38.50% |
Benchmark Metrics
Chugai Pharmaceutical Co Ltd ADR has an annualized alpha of 15.31%, beta of 0.29, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since November 23, 2010.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (56.44%) than losses (16.09%) - typical of diversified or defensive assets.
- Beta of 0.29 may look defensive, but with R2 of 0.03 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 15.31%
- Beta
- 0.29
- R²
- 0.03
- Upside Capture
- 56.44%
- Downside Capture
- 16.09%
Return for Risk
Risk / Return Rank
CHGCY ranks 33 for risk / return — below 33% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Chugai Pharmaceutical Co Ltd ADR (CHGCY) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CHGCY | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.99 | ||
| Sortino ratioReturn per unit of downside risk | -2.42 | ||
| Omega ratioGain probability vs. loss probability | 1.00 | 1.32 | -0.32 |
| Calmar ratioReturn relative to maximum drawdown | -0.29 | 2.46 | -2.75 |
| Martin ratioReturn relative to average drawdown | -0.62 | 10.92 | -11.54 |
Dividends
Dividend History
Chugai Pharmaceutical Co Ltd ADR provided a 1.85% dividend yield over the last twelve months, with an annual payout of $0.43 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.43 | $0.43 | $0.19 | $0.00 | $0.15 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.08 | $0.08 |
Dividend yield | 1.85% | 1.62% | 0.86% | 0.00% | 1.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.64% | 1.41% |
Monthly Dividends
The table displays the monthly dividend distributions for Chugai Pharmaceutical Co Ltd ADR. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.43 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.43 |
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.19 | $0.19 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.15 | $0.15 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Dividend Yield & Payout
Dividend Yield
Chugai Pharmaceutical Co Ltd ADR has a dividend yield of 1.85%, which is quite average when compared to the overall market.
Payout Ratio
Chugai Pharmaceutical Co Ltd ADR has a payout ratio of 95.64%, which is above the market average. This might signify the company's strong earnings or financial health. However, it could also hint at a more mature business phase with potentially slower growth.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Chugai Pharmaceutical Co Ltd ADR. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Chugai Pharmaceutical Co Ltd ADR was 59.68%, occurring on Nov 9, 2022. Recovery took 610 trading sessions.
The current Chugai Pharmaceutical Co Ltd ADR drawdown is 31.69%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -59.68%Nov 2022 | 1y 10mo | 2y 5mo | 4y 3moJan 2021 - Apr 2025 |
2015 bear market2015 | -38.78%Jan 2015 | 4mo 21d | 7mo 9d | 12moAug 2014 - Aug 2015 |
2025 bear market2025 | -32.48%Aug 2025 | 3mo 3d | 6mo 9d | 9mo 12dMay 2025 - Feb 2026 |
2026 bear market2026 | -32.19%Jun 2026 | 3mo 9d | — | 3mo 24dMar 2026 - now |
2016 bear market2016 | -32.07%Dec 2016 | 1y 3mo | 7mo 9d | 1y 10moAug 2015 - Jul 2017 |
Drawdown Indicators
| CHGCY | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -59.68% | -56.78% | -2.90% |
Max Drawdown (1Y)Largest decline over 1 year | -32.19% | -9.10% | -23.09% |
Max Drawdown (3Y)Largest decline over 3 years | -33.18% | -18.90% | -14.28% |
Max Drawdown (5Y)Largest decline over 5 years | -45.45% | -25.43% | -20.02% |
Max Drawdown (10Y)Largest decline over 10 years | -59.68% | -33.92% | -25.76% |
Current DrawdownCurrent decline from peak | -31.69% | -3.21% | -28.48% |
Average DrawdownAverage peak-to-trough decline | -16.12% | -10.71% | -5.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.07% | 2.04% | +13.03% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Chugai Pharmaceutical Co Ltd ADR over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Chugai Pharmaceutical Co Ltd ADR is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for CHGCY, comparing it with other companies in the Drug Manufacturers - General industry. Currently, CHGCY has a P/E ratio of 25.7. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for CHGCY compared to other companies in the Drug Manufacturers - General industry. CHGCY currently has a PEG ratio of 2.2. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CHGCY relative to other companies in the Drug Manufacturers - General industry. Currently, CHGCY has a P/S ratio of 9.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CHGCY in comparison with other companies in the Drug Manufacturers - General industry. Currently, CHGCY has a P/B value of 6.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CHGCY
Add Chugai Pharmaceutical Co Ltd ADR to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CHGCY